
Opinion|Videos|December 6, 2024
Overview of Bispecifics for R/R Multiple Myeloma
Author(s)Binod Dhakal, MD, MS
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease. Key challenges include managing cytokine release syndrome, developing optimal sequencing strategies, addressing drug resistance, and improving accessibility and affordability of novel therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the treatment landscape evolved in RRMM?
- Please elaborate on the role of bispecific T-cell engagers (BiTEs) as well as the development of BiTE targets beyond BCMAs, focusing on GPRC5D.
- What are the key unmet needs and challenges in managing patients with RRMM?
- What are the main barriers to effective treatment and optimal outcomes for this patient population?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















